Morgan Stanley
CAPR icon

Morgan Stanley’s Capricor Therapeutics CAPR Stock Holding History

Morgan Stanley’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.9M Sell
423,819
-162,021
-28% -$4.32M ﹤0.01% 3345
2025
Q4 		$16.9M Buy
585,840
+34,146
+6% +$446K ﹤0.01% 3090
2025
Q3 		$3.98M Buy
551,694
+1,113
+0.2% +$8.2K ﹤0.01% 4334
2025
Q2 		$5.47M Sell
550,581
-264,784
-32% -$2.8M ﹤0.01% 3993
2025
Q1 		$7.74M Buy
815,365
+183,611
+29% +$2.55M ﹤0.01% 3559
2024
Q4 		$8.72M Buy
631,754
+500,238
+380% +$8.77M ﹤0.01% 3517
2024
Q3 		$2M Buy
131,516
+52,321
+66% +$259K ﹤0.01% 4652
2024
Q2 		$378K Sell
79,195
-32,402
-29% -$181K ﹤0.01% 5418
2024
Q1 		$758K Buy
111,597
+16,221
+17% +$78.4K ﹤0.01% 5119
2023
Q4 		$466K Buy
95,376
+52,688
+123% +$171K ﹤0.01% 5642
2023
Q3 		$146K Sell
42,688
-10,444
-20% -$58.7K ﹤0.01% 5714
2023
Q2 		$254K Buy
53,132
+10,134
+24% +$44.5K ﹤0.01% 5539
2023
Q1 		$181K Buy
42,998
+346
+0.8% +$1.49K ﹤0.01% 5745
2022
Q4 		$165K Buy
42,652
+2,950
+7% +$14.1K ﹤0.01% 5746
2022
Q3 		$238K Buy
39,702
+1,820
+5% +$9.31K ﹤0.01% 5646
2022
Q2 		$132K Buy
37,882
+4,137
+12% +$14.7K ﹤0.01% 6124
2022
Q1 		$116K Buy
33,745
+534
+2% +$2.11K ﹤0.01% 6227
2021
Q4 		$98K Sell
33,211
-17,452
-34% -$61.1K ﹤0.01% 6449
2021
Q3 		$204K Buy
50,663
+6,213
+14% +$28.3K ﹤0.01% 5991
2021
Q2 		$228K Buy
44,450
+14,000
+46% +$59.3K ﹤0.01% 5947
2021
Q1 		$143K Sell
30,450
-25,157
-45% -$145K ﹤0.01% 5838
2020
Q4 		$191K Buy
55,607
+10,764
+24% +$46.7K ﹤0.01% 5613
2020
Q3 		$235K Buy
44,843
+9,372
+26% +$54.6K ﹤0.01% 5024
2020
Q2 		$163K Buy
35,471
+33,746
+1,956% +$147K ﹤0.01% 5173
2020
Q1 		$2K Hold
1,725
– – ﹤0.01% 6370
2019
Q4 		$2K Sell
1,725
-1,691
-50% -$3.49K ﹤0.01% 6492
2019
Q3 		$13K Buy
3,416
+3,346
+4,780% +$11.6K ﹤0.01% 6127
2019
Q2 		$0 Buy
+70
New +$293 ﹤0.01% 6648
2018
Q2 		– Hold
0
– – – 6666
2018
Q1 		– Hold
0
– – – 6614
2017
Q3 		– Sell
-2,400
Closed -$20K – 6533
2017
Q2 		$20K Hold
2,400
– – ﹤0.01% 6087
2017
Q1 		$81K Sell
2,400
-1,500
-38% -$41.6K ﹤0.01% 5676
2016
Q4 		$104K Sell
3,900
-250
-6% -$7.49K ﹤0.01% 5559
2016
Q3 		$135K Sell
4,150
-21
-0.5% -$790 ﹤0.01% 5190
2016
Q2 		$165K Sell
4,171
-3
-0.1% -$106 ﹤0.01% 5026
2016
Q1 		$106K Sell
4,174
-1,434
-26% -$34.8K ﹤0.01% 5293
2015
Q4 		$173K Buy
5,608
+1,450
+35% +$57.7K ﹤0.01% 5160
2015
Q3 		$169K Buy
4,158
+518
+14% +$23.1K ﹤0.01% 5166
2015
Q2 		$184K Buy
3,640
+752
+26% +$47.2K ﹤0.01% 5279
2015
Q1 		$249K Buy
+2,888
New +$249K ﹤0.01% 5089

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley's CAPR Position: Q1 2026 in Review

Morgan Stanley reduced its Capricor Therapeutics (CAPR) stake by 28% in Q1 2026, selling an estimated $4.32M and leaving 423,819 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3345.

Morgan Stanley first reported a position in CAPR in Q1 2015 and has held it in 38 quarters since. The position peaked at $16.9M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Morgan Stanley held 423,819 shares of Capricor Therapeutics worth $12.9M as of Q1 2026.
  • Morgan Stanley sold 162,021 Capricor Therapeutics shares in Q1 2026, an estimated $4.32M.
  • Capricor Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3345 holding.
  • Morgan Stanley first reported a position in Capricor Therapeutics in Q1 2015 and has held it in 38 quarters since.
  • Morgan Stanley's Capricor Therapeutics position peaked at $16.9M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.